Abstract: Provided is a method for the electrochemical conversion of carbon dioxide to fuels. The method employs reducing CO2 in an electrochemical cell using an aerogel carbon electrode and an ionic liquid membrane, thereby providing a carbon-based combustible.

Abstract: An optical coherence tomography (OCT) imager comprising: a low coherence light source that provides light; a photosensor for imaging light; optics that directs a first portion of the light along a first optical path so that it is imaged on the photosensor and a second portion of the light along a second optical path so that it is reflected by material in the target to the photosensor where it is imaged to interfere with light from the first portion to form an interference pattern; and a mask through which light from at least one of the first and second portions of light passes that generates a relative phase perturbation between portions of light that passes through it.

Abstract: The present invention relates generally to the mitochondrial protein, voltage-dependent anion channel (VDAC), polynucleotides encoding same and variants thereof, as well as peptide fragments, peptide derivatives and analogs. In particular, the present invention is directed to VDAC1 and specific amino acid and polynucleotide sequences thereof useful in inducing or regulating apoptosis and to pharmaceutical compositions comprising same useful in the treatment of diseases associated with aberrant apoptosis.

Abstract: There is provided herein a membrane or film comprising one or more aromatic ionomers covalently crosslinked through aryl-aryl (—Ar—Ar—), aryl-ether-aryl (—Ar—O—Ar—), aryl-sulfide-aryl (—Ar—S—Ar—), aryl-sulfone-aryl bonds, or any combination thereof, wherein said one or more aromatic ionomers further comprises at least one electron withdrawing group adapted to improve oxidant resistance of said membrane or film.

Abstract: The present invention relates generally to variants and peptides of the mitochondrial protein, voltage-dependent anion channel (VDAC) and to polynucleotides encoding same. In particular, the present invention is directed to N-terminal truncated and mutated VDAC and specific amino acid and polynucleotide sequences thereof useful in inhibiting apoptosis, and to pharmaceutical compositions comprising same useful in the treatment of diseases associated with excess apoptosis.

Abstract: The present invention relates generally to the mitochondrial protein, voltage-dependent anion channel (VDAC), polynucleotides encoding same and variants thereof, as well as peptide fragments, peptide derivatives and analogs. In particular, the present invention is directed to VDAC1 and specific amino acid and polynucleotide sequences thereof useful in inducing or regulating apoptosis and to pharmaceutical compositions comprising same useful in the treatment of diseases associated with aberrant apoptosis.

Abstract: The present invention relates generally to the down regulation of mitochondrial protein, voltage-dependent anion channel (VDAC1) expression by RNAi or antisense therapy. In particular, the present invention is directed to VDAC1 silencing molecules useful in regulating cell proliferation and to pharmaceutical compositions comprising same useful in the treatment of diseases associated with aberrant cell proliferation.

Abstract: The present invention relates generally to the mitochondrial protein, voltage-dependent anion channel (VDAC)5 polynucleotides encoding same and variants thereof, as well as peptide fragments, peptide derivatives and analogs. In particular, the present invention is directed to VDAC1 and specific amino acid and polynucleotide sequences thereof useful in inducing or regulating apoptosis and to pharmaceutical compositions comprising same useful in the treatment of diseases associated with aberrant apoptosis.

Abstract: The present invention relates generally to the down regulation of mitochondrial protein, voltage-dependent anion channel (VDAC1), expression by RNAi or antisense therapy. In particular, the present invention is directed to VDAC1 silencing molecules useful in regulating cell proliferation and to pharmaceutical compositions comprising same useful in the treatment of diseases associated with aberrant cell proliferation.